Stock listing

NASDAQ:IRON Disc Medicine, Inc. Stock

Home listing (NASDAQ) of Disc Medicine, Inc.

Follow Disc Medicine, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IRON

$75.14 USD -2.84 (-3.6%)

Close on Nov 20, 2026

Past year -16.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$74.54 – $77.01 USDNov 20, 2026
Volume
561,636 sharesNov 20, 2026
Market cap
$3.42B USDAt the close on Nov 20, 2026 · price × 45.54M shares outstanding
52-week range
$40.00 – $99.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$70.28M USDMedian day 669,013 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Disc Medicine, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IRON · Home$75.14 USD-2.84 (-3.6%)561,636$75.20$77.01$74.54$77.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IRON · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$75.14-2.84-3.6%$75.20$77.01$74.54561,636
$77.98+1.41+1.8%$76.52$79.71$75.25947,865
$76.57-0.020.0%$76.69$77.90$75.34520,620
$76.59-3.41-4.3%$80.12$80.37$76.40816,009
$80.00-3.23-3.9%$83.00$83.00$79.73778,194
$83.23-3.85-4.4%$86.16$87.14$82.66761,213
$87.08+2.44+2.9%$85.24$87.51$83.50669,013
$84.64+3.38+4.2%$80.58$86.26$80.531,925,406
$81.26+2.35+3.0%$80.83$81.54$76.86912,029
$78.91+0.44+0.6%$78.65$79.52$77.67717,525
$78.47-4.81-5.8%$83.00$85.00$78.31930,368
$83.28+2.12+2.6%$81.50$83.57$80.781,428,044
$81.16+2.54+3.2%$79.41$81.72$79.081,543,632
$78.62-2.22-2.7%$80.99$81.39$78.04525,360
$80.84-2.00-2.4%$82.79$83.03$78.61684,972
$82.84-0.36-0.4%$83.51$85.00$82.22686,454
$83.20+3.30+4.1%$78.88$83.64$78.881,071,161
$79.90+2.24+2.9%$77.23$80.50$76.501,469,720
$77.66+3.15+4.2%$74.80$78.03$74.801,203,251
$74.51-0.52-0.7%$74.29$75.56$74.011,963,099
$75.03-0.97-1.3%$75.25$78.00$74.771,588,205
$76.00-3.48-4.4%$77.80$81.50$75.894,639,550
$79.48+0.55+0.7%$79.21$80.00$74.522,206,622
$78.93+22.09+38.9%$72.70$80.22$69.988,493,179
$56.84+0.19+0.3%$56.56$57.24$55.00569,100
$56.65+0.91+1.6%$56.66$58.09$55.95699,800
$55.74-0.86-1.5%$56.21$58.84$55.48430,700
$56.60-3.88-6.4%$60.16$60.48$56.47599,000
$60.48-1.58-2.5%$62.20$62.76$60.36657,200
$62.06+1.29+2.1%$60.67$63.50$60.03691,100
$60.77-0.41-0.7%$60.71$61.58$58.22846,800
$61.18-0.47-0.8%$61.20$62.97$60.02562,800
$61.65-1.68-2.7%$63.70$64.66$61.311,422,400
$63.33-1.18-1.8%$65.13$65.57$63.01456,300
$64.51+0.90+1.4%$64.56$66.55$63.81684,700
$63.61-1.85-2.8%$65.27$65.94$63.50771,800
$65.46-0.41-0.6%$66.08$66.08$64.24671,500
$65.87+0.95+1.5%$64.93$66.29$64.05784,100
$64.92-0.32-0.5%$64.83$66.26$63.96480,500
$65.24-1.20-1.8%$66.89$66.89$64.59427,200
$66.44+0.35+0.5%$66.09$66.58$64.31455,600
$66.09-2.39-3.5%$68.54$68.95$65.31541,800
$68.48-0.010.0%$69.65$69.79$67.68450,800
$68.49-1.04-1.5%$69.84$69.84$67.16406,500
$69.53+0.35+0.5%$69.13$69.60$67.711,077,100
$69.18+0.61+0.9%$69.84$72.07$68.47621,200
$68.57+1.27+1.9%$67.88$70.00$67.49433,800
$67.30-1.62-2.4%$68.86$69.45$66.72603,900
$68.92-1.14-1.6%$70.06$70.83$67.52695,000
$70.06-4.08-5.5%$74.66$75.00$69.28621,000
$74.14-2.37-3.1%$75.89$76.59$73.16480,900
$76.51-0.33-0.4%$76.55$77.27$75.24719,500
$76.84-2.39-3.0%$76.71$79.13$74.50463,300
$79.23-0.14-0.2%$78.14$80.01$78.14204,800
$79.37-0.68-0.8%$80.34$80.89$78.28501,000
$80.05+1.38+1.8%$79.44$81.01$77.68522,500
$78.67+0.020.0%$78.56$79.95$75.88549,400
$78.65-1.38-1.7%$79.19$80.53$77.50882,000
$80.03-2.52-3.1%$81.79$82.70$79.77665,600
$82.55-0.12-0.1%$82.25$83.20$81.10324,100
$82.67+0.26+0.3%$82.28$83.63$81.54586,900
$82.41+1.47+1.8%$81.99$83.59$81.77320,944
$80.94+1.13+1.4%$79.88$82.74$79.33277,237
$79.81+0.97+1.2%$79.50$80.00$77.99370,400
$78.84-1.48-1.8%$79.45$80.15$78.49333,600

Splits

1 split · NASDAQ:IRON · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NASDAQ:IRON
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Disc Medicine, Inc. news

Disc Medicine, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 132 in all · newest Nov 5, 2026 · oldest 2021
Decks
17 decks · latest Oct 19, 2026

Where Disc Medicine, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IRON · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IRONBOATSUnited StatesUSD

Valuation

Price/book 5.7× against a median of 3.9×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.80B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
0.94

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Tango Therapeutics, Inc. · NASDAQ:TNGXUS$3.68BUS$2.74Bn/an/an/a3.8×n/a0.0×1.41
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.56BUS$3.42B7.6×5.1×n/a2.7×69.9%0.0×n/a
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Caliway Biopharmaceuticals Co Ltd · TWSE:6919US$3.38BUS$3.27Bn/an/an/a12.7×n/a0.0×n/a
Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLXUS$3.35BUS$2.58Bn/an/an/a4.4×n/a0.0×1.21
Iovance Biotherapeutics, Inc. · NASDAQ:IOVAUS$3.19BUS$2.86Bn/a7.5×n/a3.9×−58.2%0.1×1.62
Median of the othersUS$3.41BUS$2.72B7.6×54.9×3.9×5.8%0.0×1.21

Forecasts

12 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
127.69 USD · Analysts' mean
EPS, year to Dec 2026
-6.11 · 9 analysts

Team and board

Officers

OfficerRole
John QuiselChief Executive Officer
Jean FranchiChief Financial Officer
Jonathan YuChief Operating Officer
Rahul KharaChief Legal Officer
Joseph BeaulieuSVP, Finance
Melanie ChinSVP, Clinical Development and Head of Medical Affairs
Sonia RazzettiSVP, Quality
Srikanth VenkatramanSVP, Head of Chemistry
Hua YangChief Early Development Officer
Lisa Amaya PriceChief Human Resources Officer
Pamela StephensonChief Commercial Officer
Rahul Rajan KaushikChief Technical Officer
Steve CafféChief Regulatory Officer
Will SavageChief Medical Officer

Board

DirectorRole
Hua YangChief Early Development Officer
Jean FranchiChief Financial Officer
John QuiselChief Executive Officer
Jonathan YuChief Operating Officer
Joseph BeaulieuSVP, Finance
Lisa Amaya PriceChief Human Resources Officer
Melanie ChinSVP, Clinical Development and Head of Medical Affairs
Pamela StephensonChief Commercial Officer
Rahul KharaChief Legal Officer
Rahul Rajan KaushikChief Technical Officer
Sonia RazzettiSVP, Quality
Srikanth VenkatramanSVP, Head of Chemistry

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−5.8%
Q2 2026Jul 30, 2026 · Before open+7.5%
Q1 2026May 5, 2026 · Before open−0.1%
Q4 2025Feb 26, 2026−0.4%
Q3 2025Nov 6, 2025 · Before open−1.5%
Q2 2025Aug 7, 2025 · Before open−3.3%
Q1 2025May 7, 2025 · Before open+2.3%
Q4 2024Mar 19, 2025 · Before open+1.7%
Q3 2024Nov 12, 2024 · Before open−5.0%
Q2 2024Aug 8, 2024 · Before open+3.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+4.9%
Q4 2023Mar 21, 2024 · Before open−7.5%
Q3 2023Nov 9, 2023 · Before open+1.4%
Q2 2023Aug 11, 2023 · Before open+1.7%
Q1 2023May 15, 2023 · Before open−3.6%
Q4 2022Mar 31, 2023 · Before open−3.9%
Q3 2022Nov 10, 2022 · Before open+0.6%
Q2 2022Aug 11, 2022 · Before open−4.0%
Q1 2022May 6, 2022 · Before open−1.3%
Q4 2021Mar 10, 2022 · Before open−3.9%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update22 slidesOct 19, 2026
Investor Presentation (September 2026)Investor deck63 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck41 slidesJun 15, 2026
Corporate Update (February 2026)Corporate update11 slidesFeb 17, 2026
J.P. Morgan 44th Annual Healthcare Conference 2026Conference31 slidesJan 12, 2026
2025 ASH Management CallConference31 slidesDec 8, 2025
Investor Presentation (October 2025)Investor deck61 slidesOct 20, 2025
2024 ASH Management CallConference45 slidesDec 9, 2024
Corporate Update (November 2024)Corporate update16 slidesNov 4, 2024
2024 EHA Management CallConference56 slidesJun 14, 2024
All 17 decks
DeckKindSlidesDate
Technical Presentation (December 2023)Technical49 slidesDec 12, 2023
ASH 2023Conference15 slidesDecember 2023
Investor Presentation (June 2023)Investor deck54 slidesJun 9, 2023
Merger or Acquisition (January 2023)Merger or acquisition13 slidesJan 23, 2023
Merger or Acquisition (August 2022)Merger or acquisition52 slidesAug 10, 2022
ASH 2021 (American Society of Hematology Annual Meeting)Conference13 slidesNov 8, 2021
Technical PresentationTechnical19 slides

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: US$450M · US$75 a share · Jefferies +6
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), LifeSci Capital, BMO Capital Markets, H.C. Wainwright & Co.
Use of proceeds: Fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, pre-commercialization activities, working capital
Oct 21, 2026
Public offering of common stock and pre-funded warrants
Made bigger: about US$225M · US$84 a share · Jefferies +5
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, working capital and general corporate purposes
Oct 21, 2025
Public offering of common stock and pre-funded warrants
Made bigger: about US$225.5M · US$55 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead), Cantor (co-lead), BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Research and clinical development of product candidates, potential commercialization of bitopertin for EPP and XLP, working capital and general corporate purposes
Jan 22, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as FS Development Corp., a blank check company (SPAC). Priced at US$10.00 a share on Aug 11, 2020.

Price
US$10.00 a share
Shares offered
10,500,000 shares of Class A common stock
Offering size
US$105 million
Underwriters' option
Up to 1,575,000 more shares
Listing
FSDC on the Nasdaq Capital Market
Underwriter
Jefferies
Shares delivered
On or about Aug 14, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJul 2, 2020
Filed publiclyJul 24, 2020
Amended onceAug 7, 2020
Shares registered with an exchangeAug 10, 2020
Declared effective by the SECAug 11, 2020
Final prospectus, with the priceAug 13, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Aug 13, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue281.0K156.0K100.0K300.0K192.0K322.0K
Gross profit-281.0K-156.0K-100.0K-300.0K-192.0K-322.0K
Research and development170.6M96.7M69.3M33.4M25.2M28.2M
Selling, general and administrative65.4M33.0M21.9M14.0M5.76M5.87M
Operating income-236.0M-129.7M-91.1M-47.5M-30.9M-34.0M
Depreciation and amortization281.0K156.0K100.0K89.0K32.0K322.0K
EBITDA-235.7M-129.6M-91.0M-47.4M-30.9M-33.7M
Interest expense3.61M572.0K0737.0K2.16M6.83M
Income before tax-211.8M-109.0M-76.3M-46.8M-36.0M-40.8M
Income tax361.0K355.0K99.0K05.04M6.83M
Net income-212.2M-109.4M-76.4M-46.8M-36.0M-40.8M
Earnings per share, basic-6.01-3.96-3.42-45.05-40.95-2.70
Earnings per share, diluted-6.01-3.96-3.42-45.05-40.95-2.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents91.1M192.4M360.4M194.6M88.0M4.50M
Short-term investments700.0M297.4M0
Current assets803.9M493.6M365.7M198.5M90.5M5.07M
Property, plant and equipment1.16M751.0K170.0K168.0K106.0K294.0K
Total assets806.9M496.8M368.0M200.2M92.4M8.32M
Accounts payable9.02M7.95M12.6M16.2M2.56M2.38M
Current liabilities36.6M23.3M21.4M22.6M13.4M24.9M
Long-term debt29.2M28.3M404.0K4.95M
Total debt29.2M28.3M01.33M7.06M14.0M
Total liabilities67.1M53.2M22.9M23.6M14.8M30.2M
Shareholders' equity739.8M443.6M345.1M176.6M-64.2M-28.8M
Shares outstanding37.9M29.9M24.4M17.4M909.4K15.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-180.4M-93.9M-73.5M-42.3M-27.5M-32.7M
Capital spending-933.0K-505.0K-89.0K-151.0K-68.0K-22.0K
Free cash flow-181.3M-94.4M-73.6M-42.4M-27.6M-32.7M
Cash from investing-394.3M-292.3M-89.0K-151.0K-68.0K-22.0K
Cash from financing473.4M218.3M239.4M149.0M89.9M34.2M
Change in cash-101.3M-167.9M165.8M106.6M62.3M1.52M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
424B5 · ProspectusNov 5, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 26, 2026Big-stake noticeSEC
8-K · Current reportOct 22, 2026ResultsSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
424B5 · ProspectusOct 21, 2026Offer documentSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
424B5 · ProspectusOct 19, 2026Offer documentSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
144 · Notice of proposed saleOct 19, 2026Other filingsSEC
8-K · Current reportOct 19, 2026Current reportSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
8-K · Current reportSep 10, 2026Current reportSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Material contractSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
8-K · Current reportFeb 27, 2026Current reportSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
8-K · Current reportFeb 17, 2026Current reportSEC
8-K · Current reportFeb 13, 2026Current reportSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJan 7, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
8-K · Current reportDec 8, 2025Current reportSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 22, 2025Big-stake noticeSEC
8-K · Current reportOct 22, 2025Material contractSEC
424B5 · ProspectusOct 21, 2025Offer documentSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
424B5 · ProspectusOct 20, 2025Offer documentSEC
8-K · Current reportOct 20, 2025ResultsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
8-K · Current reportOct 17, 2025Current reportSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
144 · Notice of proposed saleOct 7, 2025Other filingsSEC
8-K · Current reportOct 6, 2025Management or board changeSEC
4 · Change in ownershipSep 18, 2025Insider tradeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 15, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
144 · Notice of proposed saleAug 5, 2025Other filingsSEC

This page holds 200 of 780 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Disc Medicine, Inc.’s releases · as of Oct 29, 2026

Common shares
45,540,842
Fully diluted
45,540,842

Fully diluted

LineSharesAs of
Common shares45,540,842Oct 29, 2026

Share count over time

CountShares
Oct 29, 202645,540,842

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity4.8M10.5%US$314MSep 30, 2026
BlackRock2.53M5.6%US$166MSep 30, 2026
Ra Capital Management, L.P.2.45M5.4%US$160MSep 30, 2026
Vanguard1.91M4.2%US$125MSep 30, 2026
JPMorgan1.81M4.0%US$119MSep 30, 2026
Wellington1.76M3.9%US$115MSep 30, 2026
T. Rowe Price1.66M3.6%US$108MSep 30, 2026
Vestal Point Capital, LP1.64M3.6%US$107MSep 30, 2026
State Street1.41M3.1%US$92MSep 30, 2026
Atlas Venture Life Science Advisors, LLC1.38M3.0%US$90.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
TCG Crossover Management, LLC1.34M2.9%US$87.8MSep 30, 2026
Assenagon Asset Management S.A.1.12M2.5%US$73.3MSep 30, 2026
Opaleye Management Inc.1.09M2.4%US$71.7MSep 30, 2026
Logos Global Management LP1.01M2.2%US$66.4MSep 30, 2026
Woodline Partners LP958K2.1%US$62.7MSep 30, 2026
Frazier Life Sciences Management, L.P.935K2.1%US$61.2MSep 30, 2026
Siren, L.L.C.888K2.0%US$58.2MSep 30, 2026
Geode Capital798K1.8%US$52.2MSep 30, 2026
Deerfield Management Company, L.P.657K1.4%US$43MSep 30, 2026
Saturn V Capital Management LP613K1.3%US$40.1MSep 30, 2026
abrdn598K1.3%US$39.1MSep 30, 2026
Dimensional590K1.3%US$38.7MSep 30, 2026
Two Sigma571K1.3%US$37.4MSep 30, 2026
Bellevue Group AG560K1.2%US$36.7MSep 30, 2026
Armistice Capital, LLC500K1.1%US$32.7MSep 30, 2026
Loomis Sayles & Co L P440K0.97%US$28.8MSep 30, 2026
Checkpoint Capital L.P.400K0.88%US$26.2MSep 30, 2026
Palo Alto Investors LP397K0.87%US$26MSep 30, 2026
Eventide Asset Management, LLC396K0.87%US$25.9MSep 30, 2026
Foresite Capital Management V, LLC374K0.82%US$24.5MSep 30, 2026
Baker Bros. Advisors LP350K0.77%US$22.9MSep 30, 2026
BNP Paribas311K0.68%US$20.3MSep 30, 2026
Schwab283K0.62%US$18.5MSep 30, 2026
Goldman Sachs278K0.61%US$18.2MSep 30, 2026
Octagon Capital Advisors LP270K0.59%US$17.7MSep 30, 2026
Northern Trust266K0.59%US$17.4MSep 30, 2026
Algert Global LLC252K0.55%US$16.5MSep 30, 2026
Jane Street245K0.54%US$16.1MSep 30, 2026
Bank of America236K0.52%US$15.5MSep 30, 2026
Bvf Inc233K0.51%US$15.3MSep 30, 2026
Sofinnova Investments, Inc.232K0.51%US$15.2MSep 30, 2026
First Turn Management, LLC221K0.48%US$14.4MSep 30, 2026
BNY202K0.44%US$13.2MSep 30, 2026
UBS195K0.43%US$12.8MSep 30, 2026
Catalio Capital Management, LP173K0.38%US$11.3MSep 30, 2026
Jennison Associates LLC156K0.34%US$10.2MSep 30, 2026
Trexquant Investment LP143K0.31%US$9.33MSep 30, 2026
Bain Capital Life Sciences Investors, LLC141K0.31%US$9.25MSep 30, 2026
Qube Research & Technologies Ltd137K0.30%US$8.95MSep 30, 2026
Nuveen132K0.29%US$8.65MSep 30, 2026

This page holds 50 of 229 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Strategic Advisers Fidelity U.S. Total Stock Fund1.89M4.1%US$131MMay 31, 2026
Vanguard Total Stock Market Index Fund971K2.1%US$71MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF959K2.1%US$70.1MJun 30, 2026
iShares Russell 2000 ETF740K1.6%US$54.1MJun 30, 2026
JPMorgan Mid Cap Growth Fund648K1.4%US$47.4MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.567K1.2%US$41.5MJun 30, 2026
Select Biotechnology Portfolio455K1.00%US$31.6MMay 31, 2026
Select Health Care Portfolio450K0.99%US$31.3MMay 31, 2026
Eventide Healthcare & Life Sciences Fund395K0.87%US$28.9MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund376K0.82%US$27.5MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund367K0.81%US$26.8MJun 30, 2026
Fidelity Small Cap Index Fund309K0.68%US$23.8MJul 31, 2026
Fidelity Small Cap Growth Fund278K0.61%US$21.4MJul 31, 2026
JPMorgan Small Cap Growth Fund274K0.60%US$20.1MJun 30, 2026
iShares Russell 2000 Growth ETF261K0.57%US$19.1MJun 30, 2026
Fidelity Stock Selector Small Cap Fund222K0.49%US$17.1MJul 31, 2026
VIP Mid Cap Portfolio209K0.46%US$15.3MJun 30, 2026
Loomis Sayles Small Cap Growth Fund207K0.45%US$15.1MJun 30, 2026
Fidelity Advisor Health Care Fund200K0.44%US$15.4MJul 31, 2026
PGIM Jennison Health Sciences Fund198K0.43%US$13.8MMay 29, 2026
iShares Biotechnology ETF196K0.43%US$14.4MJun 30, 2026
JNL/JPMorgan MidCap Growth Fund175K0.39%US$12.8MJun 30, 2026
Fidelity Extended Market Index Fund164K0.36%US$11.4MMay 31, 2026
Schwab U.S. Small-Cap ETF152K0.33%US$10.6MMay 31, 2026
Fidelity U.S. Equity Central Fund145K0.32%US$10.6MJun 30, 2026
Fidelity Small Cap Growth K6 Fund144K0.32%US$11.1MJul 31, 2026
Vanguard Russell 2000 Index Fund141K0.31%US$9.82MMay 31, 2026
Vanguard Explorer Fund133K0.29%US$10.3MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.132K0.29%US$9.68MJun 30, 2026
Fidelity Series Small Cap Opportunities Fund127K0.28%US$9.8MJul 31, 2026
U.S. Small Cap Portfolio122K0.27%US$9.37MJul 31, 2026
Dimensional U.S. Small Cap ETF120K0.26%US$9.23MJul 31, 2026
U.S. Micro Cap Portfolio96,9640.21%US$7.47MJul 31, 2026
JPMorgan Mid Cap Equity Fund91,7940.20%US$6.71MJun 30, 2026
JPMorgan Small Cap Blend Fund87,1660.19%US$6.38MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF83,2950.18%US$6.41MJul 31, 2026
Fidelity Advisor Biotechnology Fund80,9220.18%US$6.23MJul 31, 2026
VIP Health Care Portfolio80,0000.18%US$5.85MJun 30, 2026
Fidelity Advisor Small Cap Fund77,0000.17%US$5.36MMay 31, 2026
Vanguard Health Care Index Fund72,9900.16%US$5.08MMay 31, 2026
Schwab Small-Cap Index Fund68,5840.15%US$5.28MJul 31, 2026
Victory Science & Technology Fund64,6340.14%US$4.98MJul 31, 2026
T. Rowe Price Small-Mid Cap ETF63,7850.14%US$4.67MJun 30, 2026
Fidelity Total Market Index Fund59,6780.13%US$4.15MMay 31, 2026
BNY Mellon Small/Mid Cap Growth Fund57,8730.13%US$4.23MJun 30, 2026
Small Cap Growth Stock Portfolio56,2270.12%US$4.11MJun 30, 2026
The Hartford Healthcare Fund55,9070.12%US$4.3MJul 31, 2026
Fidelity Growth Company Fund54,6920.12%US$3.8MMay 31, 2026
Mid Cap Growth Stock Portfolio54,4290.12%US$3.98MJun 30, 2026
Select Pharmaceuticals Portfolio53,8000.12%US$3.74MMay 31, 2026

This page holds 50 of 220 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Savage William Jacob
Officer: Chief Medical Officer
Sale16,035USD 85.09US$1.36MNov 10, 2026
Bitterman Kevin
Director
Sale13,783USD 80.23US$1.11MOct 21, 2026
Bitterman Kevin
Director
Sale11,470USD 80.23US$920KOct 21, 2026
Bitterman Kevin
Director
Sale266USD 80.23US$21,341Oct 21, 2026
Bitterman Kevin
Director
Sale2,869USD 79.95US$229KOct 20, 2026
Bitterman Kevin
Director
Sale2,388USD 79.95US$191KOct 20, 2026
Bitterman Kevin
Director
Sale55USD 79.95US$4,397Oct 20, 2026
Bitterman Kevin
Director
Sale5,937USD 79.97US$475KOct 19, 2026
Bitterman Kevin
Director
Sale4,942USD 79.97US$395KOct 19, 2026
Bitterman Kevin
Director
Sale115USD 79.97US$9,197Oct 19, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Bitterman Kevin
Director
Sale27,136USD 70.11US$1.9MSep 11, 2026
Bitterman Kevin
Director
Sale912USD 79.96US$72,924Sep 4, 2026
Bitterman Kevin
Director
Sale759USD 79.96US$60,690Sep 4, 2026
Bitterman Kevin
Director
Sale18USD 79.96US$1,439Sep 4, 2026
Bitterman Kevin
Director
Sale2,810USD 79.98US$225KSep 3, 2026
Bitterman Kevin
Director
Sale2,339USD 79.98US$187KSep 3, 2026
Bitterman Kevin
Director
Sale54USD 79.98US$4,319Sep 3, 2026
Bitterman Kevin
Director
Sale26,542USD 80.17US$2.13MSep 2, 2026
Bitterman Kevin
Director
Sale22,090USD 80.17US$1.77MSep 2, 2026
Bitterman Kevin
Director
Sale511USD 80.17US$40,967Sep 2, 2026
Bitterman Kevin
Director
Sale10USD 80.98US$810Sep 2, 2026
Bitterman Kevin
Director
Sale9USD 80.98US$729Sep 2, 2026
Bitterman Kevin
Director
Sale2USD 80.98US$162Sep 2, 2026
Bitterman Kevin
Director
Sale70USD 79.95US$5,597Sep 1, 2026
Bitterman Kevin
Director
Sale58USD 79.95US$4,637Sep 1, 2026
Bitterman Kevin
Director
Sale1USD 79.95US$80Sep 1, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale8,796USD 83.12US$731KAug 25, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale300USD 82.53US$24,759Aug 24, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale8,400USD 78.11US$656KAug 17, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale12,712USD 79.20US$1.01MAug 17, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale11,888USD 79.84US$949KAug 17, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale804USD 82.64US$66,443Aug 12, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale5,000USD 80.00US$400KAug 6, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale9,704USD 74.27US$721KJul 13, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale16,896USD 74.95US$1.27MJul 13, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale6,400USD 76.05US$487KJul 13, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale100USD 82.50US$8,250Jul 7, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale1,649USD 75.00US$124KJun 29, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale300USD 72.50US$21,750Jun 26, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale851USD 75.00US$63,825Jun 26, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale9,700USD 72.66US$705KJun 22, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale22,927USD 69.92US$1.6MJun 18, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale9,522USD 70.70US$673KJun 18, 2026
Quisel John D
Director, Officer: Chief Executive Officer
Sale1,551USD 71.61US$111KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale5,400USD 69.94US$378KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale1,600USD 70.73US$113KJun 18, 2026
Khara Rahul
Officer: Chief Legal Officer
Sale500USD 71.62US$35,810Jun 18, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale11,651USD 68.76US$801KJun 16, 2026
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
Sale6,961USD 69.92US$487KJun 16, 2026
Franchi Jean M.
Officer: Chief Financial Officer
Sale6,257USD 69.24US$433KApr 14, 2026

This page holds 50 of 53 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
FMR LLC12.80%4.88MJun 30, 2026Schedule 13G
AI DMI LLC6.60%2.94MOct 22, 2026Schedule 13D
Ra Capital Management, L.P.5.90%2.23MDec 30, 2025Schedule 13G
Orbimed Advisors LLC4.50%1.56MMar 10, 2025Schedule 13D
Atlas Venture Fund X, L.P.2.20%813KDec 12, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jean George
Other companies: Cyteir Therapeutics Inc (Director · Jun 17, 2021 – Feb 14, 2024 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Jun 11, 2021 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Jan 22, 2020 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 28, 2013 · Past); Zeltiq Aesthetics Inc (Director · Oct 18, 2011 – Jul 22, 2015 · Past)
Director · Feb 5, 2021 – Feb 5, 2021 · Past
Jason Rhodes
Other companies: Dyne Therapeutics, Inc. (Chairman · Since at least Sep 16, 2020); Generation Bio Co (Director · Since at least Jun 11, 2020); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past)
Director · Feb 5, 2021 – Oct 4, 2021 · Past
Jean Franchi
Other companies: Biodesix, Inc. (Director · Since at least Oct 27, 2020); Replimune Group, Inc. (Chief Financial Officer · Dec 9, 2019 – May 16, 2023 · Past); Merrimack Pharmaceuticals Inc (Chief Financial Officer · Feb 15, 2018 – Dec 11, 2018 · Past)
Chief Financial Officer · Since at least Feb 7, 2024
Donald William Nicholson
Other companies: Generation Bio Co (Director · Since at least Jan 11, 2021); Kymera Therapeutics, Inc. (Director · Jun 16, 2021 – Jun 15, 2022 · Past)
Director · Since at least Dec 29, 2022
Georges Gemayel
Other companies: Supernus Pharmaceuticals, Inc. (INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Feb 21, 2020); Momenta Pharmaceuticals Inc (Director · Jun 19, 2019 – Oct 1, 2020 · Past)
Director · Since at least Apr 29, 2021
Gregg Beloff
Other companies: Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past); Synlogic Inc (See Remarks · Oct 21, 2019 – Dec 6, 2021 · Past)
Chief Financial Officer · Feb 5, 2021 – Feb 5, 2021 · Past
John Quisel
Other companies: Gossamer Bio, Inc. (Director · Since at least Nov 28, 2023); Acceleron Pharma Inc (EVP, Chief Business Officer · Sep 18, 2013 – Jan 2, 2020 · Past)
Chief Executive Officer · Since at least Dec 29, 2022
Mona Ashiya
Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Sierra Oncology Inc (Director · Jun 8, 2021 – Jul 1, 2022 · Past)
Director · Since at least Dec 29, 2022
Pamela Stephenson
Other companies: Zynerba Pharmaceuticals Inc (Director · Jun 14, 2022 – Oct 10, 2023 · Past); Albireo Pharma Inc (Chief Commercial Officer · Apr 22, 2022 – Mar 2, 2023 · Past)
Chief Commercial Officer · Since at least Feb 26, 2024
William Richard White
Other companies: Akero Therapeutics Inc (Chief Financial Officer · Since at least Jun 10, 2025); Ventyx Biosciences Inc (Director · Since at least Jun 5, 2025)
Director · Since at least Jun 11, 2025
All 27 people
PersonSeat
Dennis D Ryan
Other companies: Pardes Biosciences Inc (Chief Financial Officer · Feb 16, 2021 – Feb 16, 2021 · Past)
Chief Financial Officer · Aug 11, 2020 – Aug 11, 2020 · Past
Joseph Beaulieu
Other companies: Epizyme Inc (See Remarks · Aug 9, 2022 – Aug 12, 2022 · Past)
SVP, Finance · Since at least Nov 5, 2026
Brian Richard MacDonaldChief Innovation Officer · Dec 29, 2022 – Jun 28, 2023 · Past
Hua YangChief Early Development Officer · Since at least Nov 5, 2026
Jason Patrick MeyenburgChief Executive Officer, Director · Feb 5, 2021 – Jan 3, 2022 · Past
Jonathan YuChief Operating Officer · Since at least Dec 29, 2022
Lisa Amaya PriceChief Human Resources Officer · Since at least Jan 12, 2026
Mark ChinDirector · Since at least Jun 11, 2025
Melanie ChinSVP, Clinical Development and Head of Medical Affairs · Since at least May 14, 2025
Precillia RedmondChief People Officer · Feb 5, 2021 – Feb 23, 2021 · Past
Rahul KharaChief Legal Officer · Since at least Dec 29, 2022
Rahul Rajan KaushikChief Technical Officer · Since at least Nov 12, 2024
Sonia RazzettiSVP, Quality · Since at least Nov 5, 2026
Srikanth VenkatramanSVP, Head of Chemistry · Since at least Nov 5, 2026
Steve CafféChief Regulatory Officer · Since at least Nov 12, 2024
William Jacob SavageChief Medical Officer · Since at least Dec 29, 2022
Will SavageChief Medical Officer · Since at least Apr 15, 2026

Open People

Log in to ask 6ix AI your own questions about Disc Medicine, Inc.